study ( supplemental eAppendix 1 ), leading to the current version of the document. Clinical and biologic characteristics as well as baseline HRQoL scores were described in the overall, modified intention-to-treat [mITT] populations (mITT1: patients with
Search Results
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, Benoist Chibaudel, Lucile Bauguion, Leïla Bengrine-Lefevre, Daniel Lopez-Trabada Ataz, May Mabro, Jean-Philippe Metges, Denis Péré-Vergé, Thierry Conroy, Astrid Lièvre, Morgan Andre, Françoise Desseigne, François Goldwasser, Julie Henriques, Amélie Anota, and Pascal Hammel
Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma
Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco
between 2006 and 2012 in the National Cancer Database (NCDB). The NCDB collects information from >1,500 Commission on Cancer centers and captures >70% of incident cancer cases in the United States. 11 We abstracted patient characteristics, including age
Value of Size and Malignant Features of Lateral Lymph Nodes in Risk Stratification at Lateral Local Recurrence of Rectal Cancer: A National Cohort Study
Eline G.M. van Geffen, Tania C. Sluckin, Sanne-Marije J.A. Hazen, Karin Horsthuis, Regina G.H. Beets-Tan, Susan van Dieren, Corrie A.M. Marijnen, Pieter J. Tanis, and Miranda Kusters
characteristics were presented as numbers with percentages for categorical data, and as means with standard deviations for normally distributed continuous data. Subgroups were compared using independent t tests or chi-square tests. Oncologic outcomes (LLR, LR
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer
Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu
heterogeneity, it is appealing for clinicians to individualize treatment decisions according to relevant patient characteristics. 6 Our study focused on the case of abiraterone acetate + prednisone (AAP) as a treatment for metastatic hormone-sensitive prostate
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
representation of the progression-free survival. Data on TTF were only available for patients with complete follow-up (diagnosis in 2015–2016). Statistical Analysis Data in this study were analyzed using SAS 9.4 (SAS Institute Inc). Baseline characteristics
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le
, tumor site, and baseline ESAS-r Distress score. The target sample size was 100, based on our feasibility criteria for this 1-year study. We compared patient characteristics and PROs at baseline for screen-positive versus screen-negative patients, and for
Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer
Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy
(18.6%) underwent esophageal stent placement. Table 1 contains baseline patient characteristics stratified by intervention. The 2 groups differed in terms of race, tumor histology, tumor location in the esophagus, age, and Charlson comorbidity index
Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
Daniel Tobias Michaeli and Thomas Michaeli
drug, indication, and clinical trial characteristics. The first reviewer (D.T. Michaeli) independently retrieved data from FDA labels, which was then cross-checked by the second reviewer (T. Michaeli) with data found on ClinicalTrials.gov and associated
Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States
Ami M. Vyas, Hilary Aroke, and Stephen Kogut
explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average
Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?
Jia-Wei Lv, Yu-Pei Chen, Guan-Qun Zhou, Xu Liu, Ying Guo, Yan-Ping Mao, Jun Ma, and Ying Sun
subsequent publications, and to identify the trends of reporting quality and associated characteristics. Methods Data Source and Study Sample Data were obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting data
